P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Roxana Mehran, Yunpeng Zhu et al.|BMJ|2021Cited by 254
Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical TrialRoberto Galea, Marco Valgimigli, Federico De Marco et al.|Circulation|2021Cited by 138
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Marco Valgimigli, Roxana Mehran et al.|Journal of the American College of Cardiology|2023Cited by 119
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trialsMarco Valgimigli, Myeong‐Ki Hong, Sung‐Jin Hong et al.|The Lancet|2024Cited by 93
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial DiseaseAnna Franzone, Marco Valgimigli|JAMA Cardiology|2016Cited by 91